The impact of a delay in bringing exenatide LAR could prove disastrous to Amalyn, for competitive threats to Byetta loom around the bend, with Onglyza (saxagliptin), a joint venture between Bristol Myers and AstraZeneca in Phase III clinical development, and Novo Nordisk 's Victoza ( Iraglutide, the same class as exenatide, but with allegedly better efficacy) expected to be reviewed by a FDA Advisory Committee in March 2009.